NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer

NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer
The U.K.'s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology's Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube and peritoneal cancer who responded to platinum-based chemotherapy, regardless of their BRCA status or previous lines of treatment. NICE's appraisal helps to assure that patients in England will have access, at reduced or no cost, to Rubraca as a maintenance option under the Cancer Drugs Fund (CDF), the National Health Service (NHS) reserve to fund cancer therapies. An estimated 6,400 women are diagnosed with ovarian cancer in the U.K. every year. Despite advancements in treatment and care, relapse rates continue to be very high. Nearly 70% of patients treated with surgery and first-line chemotherapy experience a return of their cancer within three years. We welcome "the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” Victoria Clare, CEO of the ovarian cancer charity Ovacome, said in a
Subscribe or to access all post and page content.